Logo image of KRMD

KORU MEDICAL SYSTEMS INC (KRMD) Stock Fundamental Analysis

NASDAQ:KRMD - Nasdaq - US7599101026 - Common Stock - Currency: USD

3.19  +0.17 (+5.63%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KRMD. KRMD was compared to 188 industry peers in the Health Care Equipment & Supplies industry. KRMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, KRMD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KRMD had negative earnings in the past year.
KRMD had a negative operating cash flow in the past year.
KRMD had negative earnings in each of the past 5 years.
KRMD had a negative operating cash flow in each of the past 5 years.
KRMD Yearly Net Income VS EBIT VS OCF VS FCFKRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

KRMD has a Return On Assets of -19.46%. This is comparable to the rest of the industry: KRMD outperforms 50.53% of its industry peers.
The Return On Equity of KRMD (-32.41%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -19.46%
ROE -32.41%
ROIC N/A
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
KRMD Yearly ROA, ROE, ROICKRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

KRMD has a Gross Margin of 63.49%. This is in the better half of the industry: KRMD outperforms 63.83% of its industry peers.
KRMD's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for KRMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
KRMD Yearly Profit, Operating, Gross MarginsKRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

5

2. Health

2.1 Basic Checks

KRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
KRMD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KRMD has been increased compared to 5 years ago.
Compared to 1 year ago, KRMD has an improved debt to assets ratio.
KRMD Yearly Shares OutstandingKRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
KRMD Yearly Total Debt VS Total AssetsKRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

KRMD has an Altman-Z score of 7.21. This indicates that KRMD is financially healthy and has little risk of bankruptcy at the moment.
KRMD has a Altman-Z score of 7.21. This is amongst the best in the industry. KRMD outperforms 85.64% of its industry peers.
KRMD has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
KRMD has a better Debt to Equity ratio (0.02) than 65.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 7.21
ROIC/WACCN/A
WACC9.15%
KRMD Yearly LT Debt VS Equity VS FCFKRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 2.44 indicates that KRMD has no problem at all paying its short term obligations.
KRMD has a Current ratio (2.44) which is comparable to the rest of the industry.
A Quick Ratio of 2.02 indicates that KRMD has no problem at all paying its short term obligations.
KRMD has a Quick ratio (2.02) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 2.02
KRMD Yearly Current Assets VS Current LiabilitesKRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.08% over the past year.
The Revenue has grown by 19.63% in the past year. This is quite good.
The Revenue has been growing slightly by 7.76% on average over the past years.
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%17.53%

3.2 Future

The Earnings Per Share is expected to grow by 34.04% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 16.49% on average over the next years. This is quite good.
EPS Next Y0.04%
EPS Next 2Y26.66%
EPS Next 3Y34.04%
EPS Next 5YN/A
Revenue Next Year15.67%
Revenue Next 2Y15.14%
Revenue Next 3Y16.49%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KRMD Yearly Revenue VS EstimatesKRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
KRMD Yearly EPS VS EstimatesKRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.05 -0.1 -0.15 -0.2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KRMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KRMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRMD Price Earnings VS Forward Price EarningsKRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60 -80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRMD Per share dataKRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as KRMD's earnings are expected to grow with 34.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.66%
EPS Next 3Y34.04%

More info and screens

0

5. Dividend

5.1 Amount

KRMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KORU MEDICAL SYSTEMS INC

NASDAQ:KRMD (6/10/2025, 2:39:47 PM)

3.19

+0.17 (+5.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)N/A N/A
Inst Owners51.03%
Inst Owner ChangeN/A
Ins Owners6.35%
Ins Owner Change8.46%
Market Cap147.19M
Analysts80
Price Target5.61 (75.86%)
Short Float %0.8%
Short Ratio2.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.23%
Min EPS beat(2)3.88%
Max EPS beat(2)24.59%
EPS beat(4)4
Avg EPS beat(4)26.1%
Min EPS beat(4)3.88%
Max EPS beat(4)53.31%
EPS beat(8)8
Avg EPS beat(8)29.24%
EPS beat(12)12
Avg EPS beat(12)26.13%
EPS beat(16)14
Avg EPS beat(16)19.99%
Revenue beat(2)1
Avg Revenue beat(2)1.97%
Min Revenue beat(2)-2.56%
Max Revenue beat(2)6.5%
Revenue beat(4)3
Avg Revenue beat(4)4.38%
Min Revenue beat(4)-2.56%
Max Revenue beat(4)9.18%
Revenue beat(8)5
Avg Revenue beat(8)0.92%
Revenue beat(12)7
Avg Revenue beat(12)1.39%
Revenue beat(16)11
Avg Revenue beat(16)2.24%
PT rev (1m)-3.51%
PT rev (3m)-3.51%
EPS NQ rev (1m)15.38%
EPS NQ rev (3m)8.33%
EPS NY rev (1m)0.61%
EPS NY rev (3m)-12.64%
Revenue NQ rev (1m)0.49%
Revenue NQ rev (3m)1.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.2
P/FCF N/A
P/OCF N/A
P/B 9
P/tB 9.42
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.76
BVpS0.35
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.46%
ROE -32.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.49%
FCFM N/A
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
F-Score5
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 189.27%
Cap/Sales 4.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.44
Quick Ratio 2.02
Altman-Z 7.21
F-Score5
WACC9.15%
ROIC/WACCN/A
Cap/Depr(3y)239.72%
Cap/Depr(5y)210.83%
Cap/Sales(3y)5.63%
Cap/Sales(5y)4.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y0.04%
EPS Next 2Y26.66%
EPS Next 3Y34.04%
EPS Next 5YN/A
Revenue 1Y (TTM)19.63%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%17.53%
Revenue Next Year15.67%
Revenue Next 2Y15.14%
Revenue Next 3Y16.49%
Revenue Next 5YN/A
EBIT growth 1Y37.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.88%
EBIT Next 3Y41.31%
EBIT Next 5YN/A
FCF growth 1Y82.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.47%
OCF growth 3YN/A
OCF growth 5YN/A